سعر جاكافي 20مجم 56 قرص 2026

Jakavi 20 mg film-coated tablets (ruxolitinib), 56-tablet pack, marketed in Egypt by Novartis.

• Intermediate- or high-risk myelofibrosis, including primary MF, post-polycythaemia vera MF and post-essential thrombocythaemia MF.Population: AdultsDailyMed (U.S. National Library of Medicine)
• Polycythaemia vera with inadequate response to or intolerance of hydroxyurea.Population: AdultsDailyMed (U.S. National Library of Medicine)
• Steroid-refractory acute graft-versus-host disease.Population: Adults and children >= 12 yearsDailyMed (U.S. National Library of Medicine)

• Myelofibrosis and polycythaemia vera: most common haematologic (> 20%) thrombocytopenia and anaemia; non-haematologic (>= 15%) bruising, dizziness, headache and diarrhoea.International label, same formulation · DailyMed (U.S. National Library of Medicine)
• Acute GVHD: most common (> 50%) anaemia, thrombocytopenia, neutropenia, infections and oedema.International label, same formulation · DailyMed (U.S. National Library of Medicine)

• The US label lists no contraindications.International label, same formulation · DailyMed (U.S. National Library of Medicine)

• Thrombocytopenia, anaemia and neutropenia: manage by dose reduction, interruption or transfusion.International label, same formulation · DailyMed (U.S. National Library of Medicine)
• Risk of serious infections (including tuberculosis, herpes zoster, hepatitis B reactivation, PML); serious infections should resolve before starting.International label, same formulation · DailyMed (U.S. National Library of Medicine)
• Symptom exacerbation after interruption or discontinuation; non-melanoma skin cancer; lipid elevations; major adverse cardiovascular events; thrombosis; secondary malignancies (particularly in current or past smokers).International label, same formulation · DailyMed (U.S. National Library of Medicine)

• FluconazoleIncreases ruxolitinib exposure; avoid fluconazole doses > 200 mg/day and reduce the ruxolitinib dose with doses <= 200 mg/day.DailyMed (U.S. National Library of Medicine)
• Strong CYP3A4 inhibitorsIncrease ruxolitinib exposure; reduce, interrupt or discontinue doses as recommended (except in aGVHD/cGVHD).DailyMed (U.S. National Library of Medicine)

• No studies in pregnant women; in rats and rabbits adverse developmental outcomes (lower fetal weights) occurred at maternally toxic doses, without malformations.International label, same formulation · DailyMed (U.S. National Library of Medicine)
• Discontinue breastfeeding during treatment and for 2 weeks after the final dose (ruxolitinib and metabolites are present in rat milk).International label, same formulation · DailyMed (U.S. National Library of Medicine)

• Ruxolitinib: Inhibits JAK1 and JAK2, which mediate cytokine and growth-factor signalling important for haematopoiesis and immune function.